Gabe created and released his first public application at the age of 11. At 17, he was hired as an engineer at Apple where he helped bring about the first iPhone. Since then, he has studied Computer Science, Biology, Chemistry and Philosophy at Cornell University and has worked as the Senior Software Engineer at tech companies such as Glyde, Tumblr, Filemaker and more. He has an extensive background in mobile development, technology development and machine learning. While working on his PhD in computational biology at the University of Pennsylvania, he published several papers on applications of machine learning on large genomics datasets and other big data. In May 2014, he founded a tech company that built a revolutionary low-battery location acquisition technology called Acorn. Aside from his companies, Gabe enjoys rock climbing and archery with his wife, Johanna.
Charlie is a medically trained researcher and entrepreneur in health technologies. He has co-founded several successful companies at various stages – including Centauri Therapeutics, a company developing the subsequent therapeutic inventions from the Nobel Laureate inventor of PCR, and JV Avvinity with Horizon Discovery PLC; Premaitha Health, a UK public company 'NIPT' (LSE:AIM) using cell-free DNA as a diagnostic analyte for use in prenatal screening; the venture-funded Omnity, a computational linguistics search platform for inventors. He holds an MSc from Oxford in Experimental Therapeutics, focusing on immunotherapy, and more recently lectured at Imperial College on the Health Policy MSc run by Professor Lord Ara Darzi. As a doctor at the Royal Marsden and UCLH, he worked on trials for pharma, and gained Membership of the Royal College of Surgeons examination (MRCS) accreditation.
Riley is a Thiel Fellow who created a cancer vaccine with his previous company Immudicon (his high school company). He studied cell biology at Dartmouth and has worked under a visiting scientist agreement with Novartis. He conducted impactful research at Dartmouth with two publications, holds many accolades in entrepreneurship and pharma, and worked for biotech companies such as Syros Pharmaceuticals, Adimab, and Emergent Biosolutions.
Michael is a software engineer and researcher who started coding at the age of 10 and grew up coding web applications for small businesses and boutiques. He conducted three years of translational research in immunology with impacts in rheumatoid arthritis and B cell lymphoma at Dartmouth-Hitchcock Medical Clinic. At Dartmouth College, he was the personal intern to former surgeon general, C. Everett Koop, and Dr. Joseph O'Donnell and studied biology with a specialty in immunology and socio-cultural anthropology as a pre-med student. He has worked as a software engineer and entrepreneur in recent years, working as a software lead for Silicon Valley and New York City startups, including Beepi and Learn With Homer.
Adam Drake’s career as a computational biologist took off at Brandeis University where he studied biochemistry, evolutionary and computational biology with Douglas Theobald. After graduation he worked with Shelley Berger at the University Pennsylvania where he developed expertise in machine learning and the statistical analysis of genome-wide data sets. He has published several top-tier, high impact aging and cancer papers in leading publications. With extensive research and statistical analysis experience, he continues to innovate in the world of genomic analysis.
Peter Collins is a pharmaceutical business development advisor to Freenome. Mr. Collins has a strong entrepreneurial background and has held senior executive roles, including CEO, at a number of early-stage diagnostics and life sciences companies. A seasoned executive in molecular diagnostics with a wealth of experience in strategic leadership, business development and commercialization, he is currently Chief Business Officer at Premaitha Health. Mr. Collins previously served as VP, Head of Diagnostics at GlaxoSmithKline, where he led GSK’s Diagnostic Nucleus, supporting the diagnostic needs of Clinical Development Programs across all business units. Mr. Collins was formerly VP of Pharma Business Development for QIAGEN, driving the uptake of companion diagnostic programs in multiple partnerships across the pharma industry. Prior to its acquisition by QIAGEN, he was VP Business Development at DxS where he was pivotal in securing key companion diagnostic agreements for KRAS and EGFR. Peter previously served as VP of Marketing and Sales for Vysis Europe (now Abbott Molecular Diagnostics), and is a founder and board member of EPEMED, a European organization dedicated to advancing personalized medicine.